We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
21 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Vafseo (vadadustat) has been approved for the treatment of anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 150 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 450 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 300 mg tablet blister pack.
-
Designation or determinationProvisional determination
-
-
Prescription medicine decision summaryVafseo (vadadustat) is approved to treat anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
-
Prescription medicine registrationActive ingredients: vadadustat.
-
Australian Public Assessment Report (AusPAR)AusPAR for Truseltiq (infigratinib) for treatment of adults with metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.
-
Australian Public Assessment Report (AusPAR)For the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma